Abstract
This article describes recent advances in the development and biological evaluation of small molecule mGluR4 positive allosteric modulators (PAMs), and, to a lesser extent, orthosteric agonists. Due to its expression in the basal ganglia, the Family 3 GPCR metabotropic glutamate receptor subtype 4 (mGluR4) has recently garnered a great deal of attention as a putative target for the treatment of Parkinsons disease and a variety of other CNS disorders. Until 2008, with the exception of the prototypical mGluR4 PAM ( – )-PHCCC, very few small molecule tools existed to probe the role of selective activation of mGluR4. This review will focus on the explosion of novel mGluR4 PAMs reported in the past year and the further preclinical validation of mGluR4 activation as a potentially groundbreaking treatment for Parkinsons disease.
Keywords: Metabotropic, mGluR4, Parkinson's disease, allosteric, positive allosteric modulator, dopamine, PHCCC, glutamate
Current Topics in Medicinal Chemistry
Title: Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinsons Disease
Volume: 9 Issue: 10
Author(s): Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers and Corey R. Hopkins
Affiliation:
Keywords: Metabotropic, mGluR4, Parkinson's disease, allosteric, positive allosteric modulator, dopamine, PHCCC, glutamate
Abstract: This article describes recent advances in the development and biological evaluation of small molecule mGluR4 positive allosteric modulators (PAMs), and, to a lesser extent, orthosteric agonists. Due to its expression in the basal ganglia, the Family 3 GPCR metabotropic glutamate receptor subtype 4 (mGluR4) has recently garnered a great deal of attention as a putative target for the treatment of Parkinsons disease and a variety of other CNS disorders. Until 2008, with the exception of the prototypical mGluR4 PAM ( – )-PHCCC, very few small molecule tools existed to probe the role of selective activation of mGluR4. This review will focus on the explosion of novel mGluR4 PAMs reported in the past year and the further preclinical validation of mGluR4 activation as a potentially groundbreaking treatment for Parkinsons disease.
Export Options
About this article
Cite this article as:
Lindsley W. Craig, Niswender M. Colleen, Engers W. Darren and Hopkins R. Corey, Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinsons Disease, Current Topics in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/156802609789378272
DOI https://dx.doi.org/10.2174/156802609789378272 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews Addiction Liability of Pharmacotherapeutic Interventions in Obesity
Current Pharmaceutical Design Some Recent Approaches of Biologically Active Substituted Pyridazine and Phthalazine Drugs
Current Medicinal Chemistry Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Epilepsy
Current Neuropharmacology Modulation of the Maturing Gut Barrier and Microbiota: A Novel Target in Allergic Disease
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Aging Science The Protective Effect of Jatrorrhizine Against Oxidative Stress in Primary Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Transmucosal Drug Delivery- An Overview
Drug Delivery Letters CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science HIV Sex Risk Behaviors Among Heterosexual Methamphetamine Users: Literature Review from 2000 to Present
Current Drug Abuse Reviews Sodium-Assisted Formation of Binding and Traverse Conformations of the Substrate in a Neurotransmitter Sodium Symporter Model
Current Drug Discovery Technologies Neurological Disorders in Mice Lacking Glycogenes that are Mainly Expressed in Brain
CNS & Neurological Disorders - Drug Targets Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advancements in Electrochemical Biosensors for Alzheimer’s Disease Biomarkers Detection
Current Medicinal Chemistry The Low Molecular Weight Brain-derived Neurotrophic Factor Mimetics with Antidepressant-like Activity
Current Pharmaceutical Design